公开(公告)号：US20140099366A1

公开(公告)日：2014-04-10

申请号：US14105373

申请日：2013-12-13

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Susumu Kimura ,  Yosuke Ueki ,  Masami Nohara ,  Yukifumi Dota

IPC: A61K47/38 ,  A61K31/13 ,  A61K31/445

CPC classification number: A61K47/38 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/209 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/5084 ,  A61K31/13 ,  A61K31/445 ,  A61K45/06 ,  A61K2300/00

Abstract: An object of the present invention is to provide, for the case of implementing a therapeutic method in which at least two kinds of anti-dementia drugs are used together, a composition that has a good therapeutic effect on dementia, and also gives excellent compliance. Another object of the present invention is to provide a composition containing at least two kinds of anti-dementia drugs, in which release of the anti-dementia drugs from the composition is controlled, whereby a combined effect of the anti-dementia drugs can be achieved well. Still another object of the present invention is to provide a composition for which the frequency of administration and the amount taken are reduced and hence compliance can be improved, and a method of manufacturing such a composition. According to the present invention, there is provided a composition containing at least two kinds of anti-dementia drugs; such a composition containing at least one sustained-release portion containing an anti-dementia drug; and such a composition containing at least one cholinesterase inhibitor, and at least one N-methyl-D-aspartate receptor antagonist.

Abstract translation: 本发明的目的是提供一种治疗方法，其中使用至少两种抗痴呆药物，对痴呆具有良好治疗效果的组合物，并且还具有优异的依从性。 本发明的另一个目的是提供一种含有至少两种抗痴呆药物的组合物，其中控制抗痴呆药物从组合物的释放，由此可以实现抗痴呆药物的组合效果 好。 本发明的另一个目的是提供一种组合物，其给药频率和使用量减少，因此可以提高顺应性，以及制备这种组合物的方法。 根据本发明，提供了含有至少两种抗痴呆药物的组合物， 这种组合物含有至少一种含有抗痴呆药物的缓释部分; 和含有至少一种胆碱酯酶抑制剂和至少一种N-甲基-D-天冬氨酸受体拮抗剂的组合物。